Abeprazan
Abeprazan is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 1 | 1 | 5 | — | 3 | 10 |
| Esophagitis | D004941 | HP_0100633 | K20 | — | — | 4 | — | 2 | 6 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | — | 1 | 2 | — | — | 3 |
| Peptic ulcer | D010437 | — | K27 | — | — | 2 | — | 1 | 3 |
| Gastritis | D005756 | EFO_0000217 | K29.7 | — | — | 1 | — | 1 | 2 |
| Ulcer | D014456 | MPATH_579 | — | — | — | 1 | — | — | 1 |
| Atrophic gastritis | D005757 | EFO_1000826 | K29.4 | — | — | 1 | — | — | 1 |
| Non-erosive reflux disease | D000096663 | — | — | — | — | 1 | — | — | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | — | 1 |
| Helicobacter infections | D016481 | EFO_1000961 | — | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
| Drug interactions | D004347 | — | — | 4 | — | — | — | — | 4 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | — | 1 | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Abeprazan |
| INN | fexuprazan |
| Description | Fexuprazan (trade name Fexuclue) is a drug for the treatment of gastroesophageal reflux disease (GERD). It is a potassium-competitive acid blocker.
|
| Classification | Small molecule |
| Drug class | proton pump inhibitors, not dependent on acid activation |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNCc1cn(S(=O)(=O)c2cccc(F)c2)c(-c2ccc(F)cc2F)c1OC |
Identifiers
| PDB | — |
| CAS-ID | 1902954-60-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594445 |
| ChEBI ID | — |
| PubChem CID | 122662112 |
| DrugBank | DB16078 |
| UNII ID | BE52S2C1QT (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use